Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02043587|
Recruitment Status : Terminated (Original investigator for the trial has left)
First Posted : January 23, 2014
Last Update Posted : May 2, 2022
|Condition or disease||Intervention/treatment||Phase|
|Acute Lymphocytic Leukemia Adult Lymphoblastic Lymphoma||Drug: DNR Drug: VCR Drug: PEG-asp Drug: CTX Drug: Prednisone Drug: Liposomal AraC Drug: MTX Drug: LCV Drug: AraC Drug: Etoposide Drug: Dasatinib Drug: Rituximab Drug: Hydrocortisone||Phase 2|
This treatment regimen builds on the "Linker" regimen/UCSF Protocol 8707 ALL regimen backbone with the goal of improved efficacy and acceptable toxicity by substituting pegylated asparaginase for native L-asparaginase, the addition of rituximab for pre-B-cell ALL, and the addition of dasatinib for Philadelphia chromosome/BCR-ABL positive ALL, and the addition of cyclophosphamide for younger adults. In addition, the study regimen aims to reduce CNS relapse through the use of intrathecal liposomal cytarabine in place of intrathecal methotrexate for CNS relapse prophylaxis and
The regimen uses 3 modules of therapy with non-cross-resistant chemotherapy agents. Rituximab is added for a total of 8 doses for patients with pre-B-cell ALL. Dasatinib is added for patients with Ph+ ALL.
Course 1A (Induction): Daunorubicin, vincristine, PEG-asparaginase, and prednisone for all patients with the addition of cyclophosphamide for patients 18-39 years of age. Treatment is intensified for patients with disease present on a day 14 bone marrow biopsies during Induction Course 1A. In addition to standard analyses, minimal residual disease will be assessed on day 14 and remission bone marrow aspirates and correlated with outcomes.
Course 1B: High-dose methotrexate, oral 6-mercaptopurine, and PEG-asparaginase.
Course 1C: High-dose cytarabine and etoposide.
The 3 courses then repeat (2A (Intensification), 2B, 2C) followed by a final "B" cycle (3B) of high-dose methotrexate, 6-mercaptopurine, and PEG-asparaginase.
After completion of Course 3B, patients proceed to maintenance chemotherapy with monthly methotrexate, vincristine, 6-mercaptopurine, and prednisone cycles for 24 months with a single dose PEG-asparaginase given in month 1 of Maintenance.
CNS prophylaxis: Intrathecal liposomal cytarabine replaces intrathecal methotrexate CNS prophylaxis and is given every 2 weeks during the "A" Induction and Intensification courses then every 3 months during Maintenance for a total of 8 doses. Given the presence of CNS penetrating chemotherapy in the "B" and "C" cycles, intrathecal liposomal cytarabine is not given due to risk of excessive CNS toxicity.
There is a randomization to hydrocortisone or placebo premedication prior to PEG-asparaginase.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||31 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy With Liposomal Cytarabine (Depocyt®) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma|
|Study Start Date :||January 2014|
|Actual Primary Completion Date :||April 14, 2022|
|Actual Study Completion Date :||April 14, 2022|
Experimental: Chemotherapy for ALL
Course 1A: DNR 60 mg/m2 IV d1,2,3; VCR 1.4 mg/m2 d1,8,15,22 (cap 2 mg age >50); PEG-asp 2000 IU/m2 IV d16, age >50 1000 IU/m2, cap 3750 IU/m2; CTX 750 mg/m2 d1,15 age < 40; Prednisone 60 mg/m2 PO d1-28; Liposomal AraC 25 mg IT d1, 15
1B: MTX 220 mg/m2 IV then 60 mg/m2/h for 36h d2-3,d16-17; LCV 50 mg/m2 IV q6h x3 then 10 mg/m2 PO/IV q6h til MTX <0.1 uM; 6-MP 60 mg/m2 PO d2-8, d16-22; PEG-asp 2000 IU/m2 IV d18, age >50 1000 IU/m2, cap 3750 IU/m2
1C: AraC 2 g/m2 IV d1-4; Etoposide 500 mg/m2 IV d1-4
1A-C repeat x1(2A-C) then 3rd Course B (3B)
Maintenance (monthly, 24 mo): Prednisone 60 mg/m2 PO d1-5; VCR 1.4 mg/m2 IV d1 (cap 2 mg age >50); MTX 20 mg/m2 PO wkly; 6-MP 60 mg/m2 PO qd PEG-asp 2000 IU/m2 IV d16, age >50 1000 IU/m2, cap 3,750 IU/m2 (Mo. 1)
Maintenance mo. 1-4: Liposomal AraC 50 mg IT d1
Dasatinib 140 mg PO qd if Ph/BCR-ABL+; Rituximab 375 mg/m2 IV d1,15 of 1A-C, 2A (Pre-B)
1:1 randomization: hydrocortisone v. placebo before PEG-asp 1B, 2B, & Maint.
Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A
1.4 mg/m2 IV, days 1, 8, 15, 22 (cap at 2mg for ages >50) during Courses 1A, 2A; Maintenance: Day 1 during months 2-12
2,000 IU/m2 IV for ages </= 50, age > 50, 1000 IU/m2 IV Day 16, Courses 1A & 2A; Day 18, Course 1B; Day 17, Course 2B; Day 16, Maintenance, Month 1
750 mg/m2 IV, days 1 &15 for subjects <40 year of age, substitute cyclophosphamide 500 mg/m2 IV over 60 minutes every 12 hours for 4 doses on days 15 & 16 for subjects < 40 years of age if day 14 bone marrow M2 or M3; Courses 1A & 2A
60 mg/m2 orally once daily on days 1-28 during Courses 1A & 2A; Maintenance: Monthly, days 1-5
Other Name: Deltasone
Drug: Liposomal AraC
25 mg intrathecal (IT), on days 1 & 15 during Courses 1A & 2A; 50 mg intrathecal on day 1 during Maintenance Months 1 through 4
220 mg/m2 IV bolus over 15 minutes then 60 mg/m2/hour for 36 hours once on days 2-3 and 16-17 during Courses 1B & 2B; 20 mg/m2 orally one day per week every 7 days during Maintenance Months
50 mg/m2 IV over 15-30 minutes every 6 hours for 3 doses to begin immediately after completion of methotrexate infusion, then 10 mg/m2 orally or IV over 15-30 minutes every 6 hours until methotrexate level less than 0.1 micromolar during Courses 1B & 2B
Other Name: Leucovorin
2,000 mg/m2 IV, days 1-4 during Courses 1C & 2C
500 mg/m2 IV over 3 hours once daily on days 1-4 during Courses 1C & 2C
140 mg orally daily if BCR/ABL positive and/or Ph+
Other Name: Sprycel
375 mg/m2 IV once daily on days 1 & 15 (precursor B-cell ALL only, administer per institutional protocol) during Courses 1A, 1B, 1C & 2A
Other Name: Rituxan
Randomize patients proceeding to Course 1B to hydrocortisone versus placebo prior to PEG-asparaginase treatments in Courses 1B, 2B, 3B, and Maintenance month 1
- Event-free survival [ Time Frame: 3-year ]
- Liposomal cytarabine toxicity [ Time Frame: 3 years ]
- CNS relapse rate [ Time Frame: 3-year ]
- Overall survival [ Time Frame: 3-year ]
- Leukemia-free survival [ Time Frame: 3-year ]
- Efficacy of hydrocortisone premedication for reduced PEG-asparaginase allergic reactions [ Time Frame: 3 years ]
- PEG-asparaginase toxicities [ Time Frame: 3 years ]
- Complete and overall response rates [ Time Frame: 3 years ]
- Non-relapse mortality [ Time Frame: 3-year ]
- Minimal residual disease and outcomes [ Time Frame: 3 years ]
- Asparaginase antibodies and asparaginase activity [ Time Frame: 3 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02043587
|United States, California|
|UCSD, Division of Blood and Marrow Transplantation, Moores Cancer Center|
|La Jolla, California, United States, 92093|
|Hematological Malignancies/Stem Cell Transplantation Unit, David Geffen School of Medicine at UCLA|
|Los Angeles, California, United States, 90095|
|University of California Davis Comprehensive Cancer Center|
|Sacramento, California, United States, 95817|
|UCSF Comprehensive Cancer Center|
|San Francisco, California, United States, 94143-0324|
|Principal Investigator:||James K Mangan, MD, PhD||UC San Diego, Division of Blood and Marrow Transplantation|